BTK Inhibitors in CLL / SLL
December 1, 2025
The following short video with animation walks through how all the approved BTKi’s work and how resistance can develop and be overcome.
The following short video with animation walks through how all the approved BTKi’s work and how resistance can develop and be overcome.
CLL patients who received BTKi and stopped therapy for non-CLL progression reasons reported an improved quality of life and prolonged time off treatment.
October 2025 CLL Bloodline: Over the course of a year of monthly meetings, The CLL Society Bloodline will teach the BASICS needed to understand CLL.
Join CLL Society and Dr. Daphne Ruth Friedman as she delves into the unique challenges and considerations of CLL and SLL among veterans.
In patients being treated with BTK inhibitors, mutations in BTK are relatively rare (2 in 100 patients).
Double-refractory CLL is very different from double-exposed CLL, with patients with double-refractory disease having worse outcomes.
Access important medications in the CLL Society Clinician Medicine Cabinet. Download key resources and order a Welcome Kit.
NX-5948 is a novel type of drug, classified as a BTK degrader, and it has shown promising early clinical data.
CLL Society awarded Dr. Quinlan Sievers a research grant for his project studying the Discovery and Overcoming Mechanisms of Resistance to BTK Inhibitors